CTOs on the Move

Frontage Laboratories

www.frontagelab.com

 
Frontage Laboratories, Inc. is a CRO that provides integrated, science-driven, product development services throughout the drug discovery and development process to enable pharmaceutical and biotechnology companies to achieve their development goals. Comprehensive services include drug metabolism and pharmacokinetics, analytical testing and formulation development, preclinical and clinical trial material manufacturing, bioanalysis, preclinical safety and toxicology assessment and early phase clinical studies. Frontage has enabled many biotechnology companies and leading pharmaceutical companies of varying sizes to advance a myriad of molecules through development and file regulatory submissions in the United States, China and other countries.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

Hannibal Regional Hospital

Hannibal Regional Hospital Foundation is a non-profit corporation (501,(c)3) and a part of the Hannibal Regional Healthcare System which exists to support Hannibal Regional Hospital by raising privately donated money.

Stelkast

Stelkast is a Canonsburg, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OptiScan Biomedical Corp

OptiScan Biomedical Corp is a Hayward, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

vitaMedMD

vitaMedMD is a Boca Raton, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Portola

Portola Pharmaceuticals is dedicated to developing and commercializing therapies that transform patient lives and advance patient care by changing treatment paradigms in thrombosis and other hematologic diseases. Our two lead assets are Bevyxxa® (betrixaban), and andexanet alfa. In addition, cerdulatinib is our investigational Syk/JAK inhibitor to treat hematologic cancers. These compounds come from our own internal research efforts and represent important advances to address significant unmet needs. We are employing novel strategies that may increase the likelihood of clinical, regulatory and commercial success of our potentially lifesaving therapies.